Navigation Links
Watson Launches Generic FEMCON(R) Fe
Date:9/26/2011

PARSIPPANY, N.J., Sept. 26, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has launched Norethindrone and Ethinyl Estradiol Tablets (Chewable), 0.4 mg/0.035 mg and Ferrous Fumarate Tablets (Chewable), 75 mg, a generic version of Warner Chilcott's FEMCON(R) Fe. Watson began shipping the product today. FEMCON(R) Fe is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception.

For the most recent twelve months ending July 31, 2011, FEMCON(R) Fe had sales of approximately $35 million, according to IMS Health data.

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third part
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Watson to Host Conference Call and Webcast to Discuss Third Quarter 2011 Earnings
2. Watson to Present at the Jefferies 2011 Global Healthcare Conference
3. Watson Confirms Amphastar Patent Lawsuit
4. Watson Pharmaceuticals Announces Approval of Amphastars Generic LOVENOX(R)
5. Watson to Present at the 2011 Bank of America Merrill Lynch Global Healthcare Conference
6. Watson to Present at the 2011 Morgan Stanley Global Healthcare Conference
7. Watsons Anda Distribution to Build 234,000 sq ft Pharmaceutical Warehouse and Distribution Facility in Olive Branch, DeSoto County, MS
8. Watson Enters into Agreement to Acquire Products Related to Perrigos Acquisition of Paddock Laboratories
9. Watson Second Quarter 2011 Net Revenue Exceeds $1 Billion; Non-GAAP EPS of $1.01
10. Watson Confirms JALYN™ Patent Challenge
11. Watson Confirms Favorable Appeals Court Decision in Mucinex(R) Patent Suit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 2014  LABSCO, the leading specialty sales ... to hospitals, physician office laboratories and alternate ... agreement with Sysmex America.  This agreement is ... the Sysmex XS-1000 i ™, Sysmex pocH-100 ... Automated Hematology Analyzers. The agreement ...
(Date:9/18/2014)... 2014  PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial ... ended June 30, 2014. Quarter Ended ... June 30, 2014 increased $492,000, or 18%, to $3.2 ... June 30, 2013, due primarily to an increase of ... the Company,s largest customer, partially offset by an aggregate ...
(Date:9/18/2014)... --  MacPractice,s MacPractice MD MU version 5.0 has ... designates that the software is capable of supporting eligible ... Meaningful Use measures required to qualify for funding under ... MU version 5.0 was certified on June 6, 2014 ... National Coordinator-Authorized Certification Body (ONC-ACB) and is compliant in ...
Breaking Medicine Technology:LABSCO Renews Sysmex Distributorship Agreement 2LABSCO Renews Sysmex Distributorship Agreement 3Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 2Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 3Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 4Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 5Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 6Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 7Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 8Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 9Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 10Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 11Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 12Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 13MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 2MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 3MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 4MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 5
... , , ... Incorporated, (IDEV) an emerging leader in the development and marketing ... patient was enrolled in the Company,s FDA-approved multi-center clinical trial ... for the treatment of biliary and peripheral artery disease (PAD) ...
... RYE, N.Y., Aug. 24 Curemark Founder and CEO Dr. ... International Epigenomics, Sequencing 2009 Conference at Harvard Medical School on ... to address this cutting-edge conclave is particularly significant, since epigenetics ... occur without a change in the DNA sequence. Presenters at ...
Cached Medicine Technology:IDEV(R) Technologies Announces First Patient Enrolled in Multi-Center Clinical Trial of SUPERA(R) PERipheral Stent 2Curemark CEO Presents at Epigenomics Conference 2
(Date:9/18/2014)... true: exercise is good for you. But new research ... have an added benefit for cancer patients undergoing chemotherapy. ... melanoma, found that combining exercise with chemotherapy shrunk tumors ... associate professor in the School of Nursing and director ... was the senior author on the study, which appears ...
(Date:9/18/2014)... The American College of Chest Physicians (CHEST) together ... at the annual congress of CTS that CHEST ... Clinicians specializing in pulmonary, critical care, and sleep ... participate in the event, slated for spring 2016. ... rich educational experiences including hands-on simulation training, keynote ...
(Date:9/18/2014)... (PRWEB) September 19, 2014 ... the Neighborhood Mission (Misión Barrio Adentro), which ... the healthcare system (see Section 6.1.3.). In ... in an Autonomous Service of Pharmaceutical Elaborations ... plant, which provides medicines at a cheaper ...
(Date:9/18/2014)... TayganPoint Consulting Group, a leading ... and co-founder John Cassimatis was named as one ... 2014, recognizing the region’s top healthcare and life ... of the year. , The Innovation Awards celebrate ... continue to shape the medical industry in Greater ...
(Date:9/18/2014)... Salt Lake City, UT (PRWEB) September 18, 2014 ... across North America will be recognizing their shared fundraising ... on Thursday, Sept. 25. , The first-ever Dance ... of more than $20 million projected to be raised ... at their community’s CMN Hospital. Donations generated through Dance ...
Breaking Medicine News(10 mins):Health News:Exercise boosts tumor-fighting ability of chemotherapy, Penn team finds 2Health News:CHEST announces China as site of CHEST World Congress 2016 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 3Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 4Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:250 Campuses Usher in School Year of Saving Kids’ Lives During First-Ever “Dance Marathon Day” on Sept. 25 2
... services company standardizes on AVG Network Edition , ... ... Pyramid Healthcare, founded in 1999, provides behavioral healthcare services for ... and behavioral problems. The company has 23 locations across Pennsylvania, ...
... (CTI) (Nasdaq and MTA: CTIC) announced today that they ... with Spectrum Pharmaceuticals, Inc. to commercialize and develop Zevalin(R) ... the initial $7.5 million payment in connection with the ... up to an additional $15 million in product sales ...
... Immucor, Inc.,(Nasdaq: BLUD ), a global leader ... reported financial results,for the fiscal second quarter ended November 30, ... -- Revenue for the fiscal second quarter ... the same period last year. , ...
... of America,Inc. announced the formation of ROSA of ... ROSA of South Alabama is a joint ... P.C., Monroeville Radiation -,Oncology, P.C., and South Alabama ... of America, Inc. ROSA of South,Alabama will ...
... The following is a statement by Lois Aronstein, ... State address put forth recommendations on a number of ... financial security of New Yorkers of all ages.AARP commends ... Plus Program to 200 percent of the federal poverty ...
... also bolsters tie between vitamin D and the brain ... have identified nine genes that might make people more ... confirmed earlier reports that a variation in the vitamin ... risk for Alzheimer,s. Low levels of vitamin D ...
Cached Medicine News:Health News:Walling Data and AVG Restore Pyramid Healthcare's Efficiency 2Health News:Walling Data and AVG Restore Pyramid Healthcare's Efficiency 3Health News:Walling Data and AVG Restore Pyramid Healthcare's Efficiency 4Health News:Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals 2Health News:Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals 3Health News:Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals 4Health News:Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance 2Health News:Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance 3Health News:Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance 4Health News:Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance 5Health News:Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance 6Health News:Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance 7Health News:Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance 8Health News:Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance 9Health News:Ambulatory Services of America, Inc. Announces Joint Venture with Gulf Coast Cancer Centers 2Health News:9 Genes Are Linked to Alzheimer's 2
... Ad-Techs Foramen Ovale Electrodes provide you ... These electrodes offer the same proven design ... that they are placed using an introducing ... a smaller electrode body diameter, 3 to ...
... The Small Joint Ball Electrode ... in small joint applications. With its ... tip, controlled capsuloligamentous or tendinous tissue ... When used in conjunction with the ...
... is designed to replace the carpal scaphoid bone. ... pole which fits under a shelf formed in ... suture hole on the proximal hole for suture ... the early postoperative period until a firm capsuloligamentous ...
... two-piece Titanium (Ti-6Al-4V) screw offered in two ... of lengths. The two pieces are loaded ... A single instrument set contains all items ... Standard and Mini Kompressor Compression Screws. , ...
Medicine Products: